Pipeline

AI-driven solutions for gynecologic diseases

Our women's health product pipeline is focused on developing non-invasive, AI-driven solutions for gynecologic diseases. We leverage groundbreaking research to create innovative diagnostic tools, This integrated and focused approach allows us to swiftly provide valuable, individualized solutions to patients and their healthcare providers.

Ovarian Cancer

IN DEVELOPMENT

MARKETED

  • MARKETED
    0%
  • MARKETED
    0%

OvaMDX - Next Generation Ovarian Cancer Risk Assessment Product

  • IN DEVELOPMENT
    0%

Endometriosis

IN DEVELOPMENT

MARKETED

  • IN DEVELOPMENT
    0%

EndoMDX - Next Generation Endometriosis Risk Assessment Product

  • IN DEVELOPMENT
    0%

OvaMDX - Next Generation Ovarian Cancer Risk Assessment

A promising new AI-powered blood test to aid in the identification of ovarian cancer in women diagnosed with an adnexal mass.

  • Non-invasive, blood-based assay utilizing multiple, differentiating biomarkers
  • Combines Aspira's protein biomarkers with miRNAs licensed from Dana Farber and clinical data in a proprietary algorithm for:
    • Improved specificity for all stage cancers vs. proteins alone
    • Improved sensitivity for early-stage cancers vs. proteins alone
  • Platform migration in process with CRO partner

EndoCheck

Designed to aid in the diagnosis of endometriomas, which are present in approximately 40%+ of women with endometriosis.

  • Non-invasive, blood-based assay utilizing multiple, differentiating biomarkers
  • Proprietary algorithm leverages core Aspira technologies and experience

Developed with histology confirmed endometriosis and appropriate control cohorts.

Currently running clinical validation with additional patient samples in CLIA-certified laboratory environment.

EndoMDX - Next Generation Endometriosis Risk Assessment

Designed to aid in the diagnosis of all endometriosis, including the 60% not attributed to the endometrioma.

  • Expands patient population beyond endometrioma
  • Non-invasive, blood-based assay utilizing proteins, clinical factors, and miRNAs
  • Proprietary IP for miRNAs identified by DFCI under terms of our Sponsored Research Agreement
  • Platform migration underway for simple ddPCR test for Next generation ovarian cancer risk assessment; Next generation endometriosis risk assessment will follow on same BioRad platform

Connect with us to learn more or to order test kits